Why the study?
The authors sought to investigate the defibrillation safety margin and the efficacy of terminating induced ventricular fibrillation at S-ICD implantation using energies lower than the recommended 65 J.
Does low-energy shock testing (20-50 J) effectively terminate induced ventricular fibrillation in S-ICD recipients?
Does low-energy shock testing (20-50 J) effectively terminate induced ventricular fibrillation in S-ICD recipients?
Low-energy shocks (≤40 J) successfully terminate induced VF in 84% of S-ICD recipients, suggesting that a 60 J output device may provide an adequate safety margin while enabling device downsizing.
Answers are grounded in this paper and cite their sources.
Low-energy VF termination rates support cautious S-ICD energy optimization; leaves open need for randomized safety-margin trials.
BACKGROUND: The subcutaneous implantable cardioverter-defibrillator (S-ICD) is an effective alternative to the transvenous one. Defibrillation efficacy depends on maximum device output and on the optimal device location at device implantation. HYPOTHESIS: We sought to investigate the defibrillation safety margin in real life clinical practice. METHODS: We sought to understand what is the efficacy of induced ventricular fibrillation (VF) termination at S-ICD implantation using lower energies than the recommended 65 J. RESULTS: Sixty-four consecutive S-ICD recipients underwent VF termination attempts at implantation with energies ranging from 20 to 50 J. Overall, VF termination occurred in 84% of patients with ≤40 J, in 88% with 45 J, and in 100% with 60 J. Intermuscular S-ICD placement was associated with 94% VF termination at ≤40 J. An ejection fraction <35% was associated to higher energy requirement for defibrillation; however, an intermuscular S-ICD placement conferred 90% defibrillation efficacy at 31 ± 5 J in this patients subset. CONCLUSIONS: This is a hypothesis-generating observation that prompts a methodologically correct investigation to prove that a 60 J output S-ICD can provide an adequate safety margin to terminate VF in clinical practice. This would enable superior device longevity and/or device downsizing for pediatric/small size patients.
No takes yet. Share an insight, caveat, or question.
Biffi et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: